BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Company update

MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data and program updates for CARDAMYST®

Related news

MISTMilestone Pharmaceuticals Inc.2026-09-02 12:00 EST

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

MISTMilestone Pharmaceuticals Inc.2026-10-09 12:00 EST

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

BLTEBelite Bio2026-09-29 00:00 EST

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

LXRXLexicon Pharmaceuticals2026-09-01 20:05 EST

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

NAMSNewAmsterdam Pharma2026-08-26 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

RYTMRhythm Pharmaceuticals2026-08-04 20:01 EST

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

RYTMRhythm Pharmaceuticals2026-09-10 12:00 EST

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

VANIVivani Medical2026-10-12 11:00 EST

Vivani Medical Announces Participation in Upcoming Investor Conferences

SENSSenseonics2026-09-10 12:00 EST

Senseonics To Participate in Upcoming Institutional Investor Conferences

VKTXViking Therapeutics2026-09-02 20:05 EST

Viking Therapeutics to Participate at Upcoming Investor Conferences

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-10-19 12:00 EST

Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences

MISTMilestone Pharmaceuticals Inc.2026-10-09 12:00 EST

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

MISTMilestone Pharmaceuticals Inc.2026-09-24 12:00 EST

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

MISTMilestone Pharmaceuticals Inc.2026-09-02 12:00 EST

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Stock data

Close
0.70 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States